Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

About Monte Rosa Poster presentation today at 14:45 CET / 8:45 a.m. ET Summary of findings: The poster, entitled "MRT-6160, a VAV1-Directed Molecular Glue Degrader, Reduces Joint Inflammation and Autoantibody Production in a Collagen-Induced Arthritis Autoimmune Disease Model" (Poster Number 1200), will be presented today by Adam Cartwright, Ph.D., Senior Scientist II at Monte Rosa Therapeutics, at 14:45 CET / 8:45 a.m. ET. Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initi ...